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ABSTRACT: The study reports the prospective outcome of treating severe recalcitrant fracture nonunion in patients with autologous
bone marrow-derived mesenchymal stromal cells (BMSC) from 2003 to 2010 and analyze predictors of union. Autologous BMSC were
culture expanded and inserted at nonunion site with or without carriers in addition to surgical stabilization of the fracture. Radiological
union was ascertained by musculoskeletal radiologists on plain radiographs and/or CT scans. A logistic regression analysis was
performed with cell-expansion parameters (cell numbers, cell doubling time) and known clinical factors (e.g., smoking and diabetes) as
independent variables and fracture union as the dependent variable to identify the factors that influence bony healing. An Eq5D index
score assessed the effect of treatment on general quality of health. A total of 35 patients (mean age 51þ/  13 years) with established
nonunion (median 2.9 years, 1–33) and, at least one failed nonunion surgery (median 4,1–14) received treatment. Fracture union was
achieved in 21 patients (60%; 95%CI 44–75) at 2.6 years. Multiple penalized logistic regression revealed faster cell doubling time
(p¼ 0.07), absence of diabetes (p¼ 0.003), less previous surgeries (p¼0.008), and lower age at cell implantation (p¼0.02) were
significant predictors for fracture union. A significant increase in Eq5D index (p¼0.01) was noted with a mean rise of the score by 0.34
units (95%CI 0.11–0.58) at 1 year following the study. In summary, the study revealed cell doubling time as a novel in vitro parameter
in conjunction with age, multiple surgeries, and diabetes as being significant predictors of the fracture union. ß 2018 The Authors.
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A total of 850,000 new fractures are reported annually
in the UK. The majority progress to uncomplicated
healing, except in 5–10% of patients whose fracture does
not heal.1 Recent Scottish data estimates the overall
annual incidence of nonunions at 19 per 100,000 people,
equivalent to the incidence of revision hip replace-
ments.1,2 However, nonunion in young individuals can
have a devastating impact on the patient’s life for longer.
Lower limb nonunions make up 6.7 per 100,000 people,
with a treatment cost per person of $11,500 to $132,000
to the National Health Service in the UK.2
The haematoma which forms post-fracture in
humans contains cells which have multi-lineage differ-
entiation potential including the capacity for osteogenic
differentiation; the phenotype of these cells is similar to
mesenchymal stem cells (MSC).3,4 However, nonunion
stromal cells (NUSCs) grown from human nonunion
sites were noted to have slower doubling time, lower
osteogenic potential, and a higher rate of apoptosis in
comparison to bone marrow derived MSCs from healthy
donors.5 These NUSCs were also found to secrete
Dickkopf-1(Dkk-1) which is an antagonist to the Wnt
signalling pathway and inhibits osteogenic differentia-
tion and fracture healing.5
Hence, exploring autologous osteoprogenitor cells re-
mote from the site of the nonunion will be an intutive
choice. Successful regeneration of large bone defects by
using in vitro expanded autologous BMSC and subse-
quently re-implanting them in scaffolds has been reported
in one case series of four patients.6 Given that in vitro
studies have demonstrated no difference in the osteogenic
capacity of BMSC from iliac crest in patients with
atrophic nonunions and healthy volunteers,7 one could
use a similar approach in cases of nonunions. Indeed,
case series have reported success using autologous bone
marrow derived cells from iliac crest for the treatment of
nonunions, implanted either after in-vitro culture expan-
sion8,9 or as a concentrate produced immediately after
harvest.8,9 Given these promising results, we decided to
investigate the utility of using culture-expanded autolo-
gous BMSCs to treat patients with a “recalcitrant”
nonunion, which is characterized by persistence of estab-
lished nonunion (as defined by the US Food and Drug
Administration (FDA) for at least 1 year, in addition to at
least one previous failed surgery to treat the nonunion.
An additional aim was to determine baseline predictors of
successful bone healing, which could help to target the
therapy or assess the potency of the cells.
METHODS
Patients with recalcitrant nonunion were invited to partici-
pate in the study of evaluating the efficacy of autologous
BMSC in achieving fracture union.
Patient inclusion criteria were:
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a. Nonunion following fracture of the tibia or femur.
b. An established nonunion according to the US FDA crite-
ria10 for at least 1 year.
c. At least one failed previous surgery for nonunion.
Patient exclusion criteria were:
a. Skeletal immaturity.
b. Pregnant or breastfeeding.
c. Nonunion following pathological fractures.
d. Infection during BMSC culture.
In Vitro BMSC Culture
Bone marrow aspirates from the iliac crest of the patients
with nonunion were harvested with aseptic precaution in the
theatre. A Jamshidi needle attached to a heparinized syringe
(Becton Dickson Medical Supplies, Cowley, UK) was used to
aspirate between 2 and 10 ml of bone marrow (with a new
insertion site after each 2 ml). The BMSC’s were isolated and
cultured from the aspirate according to the previously
published protocol from our centre.11
These cells were plated at a density of 2 107 cells per
250 ml flask (Polystyrene Tissue Culture Flask, BD Bio-
sciences, Cowley, Oxford, UK) with 20 ml of the DMEM-
F12 10% FCS and antibiotics (Penicillin & Streptomycin).
After 24 h the non-adherent cells and medium were
removed and the flask washed with PBS. The adherent
cells were continued to be cultured in monolayer with the
same medium at 37˚C, 5% (v/v) CO2 until it reached 70%
confluence. Then the cells were passaged by trypsinization
and re-seeded at a density of 5 103 cells/cm2. Cell numbers
were counted by trypan blue exclusion at the end of each
passage and the doubling time calculated over a period of
3 weeks. The discarded medium was sent to the microbiol-
ogy department for infection screening. At 3 weeks, cells
were harvested (usually passage 3) culture and suspended
in pure autologous serum before being transported to the
operating theatre for insertion at the nonunion site by the
surgeon.
Surgical Technique
The nonunion site was exposed and decorticated to allow
implantation of the cells. Cells in autologous serum was
mixed with carriers in 27 patients (b tri-calcium phos-
phate (Allogran1-R, Biocomposites, Keele, UK), calcium
sulphate (CaSO4; Stimulan
1, Biocomposites, Keele, UK),
hydroxyapatite (Allogran1 N, Biocomposites), or a combi-
nation of b tri-calcium phosphate and calcium sulphate)
and left for 10–15 min. This allowed attachment of cells to
the carrier and subsequently the mixture was inserted at
the nonunion site. The same process occurred for the
remaining eight patients, but without the use of carriers;
rather cells suspended only in autologous serum were
applied directly to the nonunion site. Surgical stabiliza-
tion of fracture was undertaken, if required, however not
routinely carried out.
Outcome Measures
Radiological evidence of fracture union at follow-up as
assessed by independent specialized musculoskeletal radiol-
ogists was used as a primary outcome criterion for the
bony healing of the nonunion site. Any further interven-
tions for fracture fixation due to the persistence of
nonunion was defined as failure of the treatment, and the
fracture was deemed not united by the study intervention.
Surgical interventions for wound complications, pin-tract
infection following application of external fixation device,
revision of external fixator pins due to local soft-tissue
complications, dynamization, or revision of interlocking
screws following intramedullary fixation were not consid-
ered as treatment failures. The change in the EQ-5D index
at 1 year was also used as an outcome measure to assess
the impact of treatment on the general quality of life in
these patients. Safety was assessed from the occurrence of
any postoperative serious adverse events until final follow-
up. The influence of six continuous (age at fracture, time
since original fracture, number of previous operations, age
at cell implantation, number of implanted cells, cell dou-
bling time) and 11 categorical (gender, fracture site, type of
fracture, type of nonunion, presence of infection at cell
insertion, diabetes, alcohol usage, smoking, previous bone
graft treatment, previous BMP treatment, carrier type)
potential baseline and treatment-related predictors of frac-
ture union was analyzed.
Statistical Methods
Fisher’s exact test was used to identify univariable categori-
cal predictors of fracture union at the nonunion site. Penal-
ized logistic regressions were used to identify continuous
variables. Multiple penalized logistic regressions were used
in a multivariable analysis to determine if combined inde-
pendent variables gave a better prediction. For this analysis,
all univariable predictors with p< 0.25 were considered
potential candidates for inclusion in the multivariable
model.12 Nagelkerke’s R2 was used as an overall measure of
model performance.13
A multilevel model with a random intercept was used to
determine the difference in the EQ-5D index before and
1 year after treatment. This method was chosen to include
all patients, even when one of their pre or postoperative EQ-
5D score was missing.
Statistical analyses were performed using R version 3.0.2,
using the packages “logistf” and “nlme.” A two-sided p-value
below 0.05 was assumed to denote statistical significance.
RESULTS
Patient Demographics
A total of 37 patients were invited to participate in the
study; one patient did not meet the inclusion criteria,
and one patient declined participation in the study.
Hence, 35 patients (21 males, 14 females), with a
mean age of 50.6 years (range 17–75) at the time of
treatment, were recruited (Table 1). The median
duration of established nonunion was 2.9 years (range
1–33); patients had undergone a median of four
surgical interventions (range 1–24) before cell inser-
tion at the fracture site. Each patient in this cohort
met the criteria defining “recalcitrant” nonunions of
fracture. Twenty-nine patients had atrophic nonun-
ions, whereas six had hypertrophic nonunions; 19
patients had femoral, and 16 had tibial fracture
nonunions. There were no dropouts or loss to follow-up
during the first 12 months except one patient who died
from unrelated causes 3 months after the study
intervention.
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In Vitro BMSC Culture
Autologous BMSC’s were culture expanded for three
weeks with a mean cell doubling time of 7.2 days
(range 2–31, SD-6.24) and without any evidence of
infection in the media. A mean of 5.5106 BMSCs
(range 2–10106, SD 1.99106) was inserted into the
nonunion site. Twenty-seven patients (77%) received a
carrier based on b-TCP, calcium sulphate or a combi-
nation of both or hydroxyapatite (Table 2). For eight
patients (23%) autologous serum alone was used
without a carrier.
Fracture Union Rate and Predictors of Union
A total of 21 out of 35 patients (60%; 95%CI 44–
75%) achieved radiological fracture union at an
average follow-up of 2.6 years (range-0.24–8.24)
ascertained by specialist musculoskeletal radiolog-
ists in a orthopaedic tertiary care unit (Fig. 1). The
vast majority of categorical independent variables,
including the type of carrier, had a small but non-
significant effect on the union rate (Table 3). The
effect of diabetes did not reach significance,
(p¼0.06), but reduced the odds of achieving union
by over eight-fold (Table 3). Of the five patients
with diabetes, four failed to reach fracture union.
Among the continuous predictors, the number of
previous operations and the cell doubling time
during in-vitro culture of BMSCs were significant
predictors of the fracture union (Table 4).
In the multiple penalized logistic regression
analysis, we used all four univariable predictors
with p< 0.25 as potential predictors, namely hav-
ing diabetes, the number of previous surgical
interventions, age at cell implantation, and cell
doubling time. Age at accident and years since
accident were excluded due to their strong correla-
tion with age at implantation (Spearman’s rho
¼0.86; p< 0.001) and number of previous opera-
tions (Spearman’s rho¼0.60; p<0.001), respec-
tively. According to the regression model, the
chance of union was larger in patients with a lower
age at cell implantation, fewer previous surgical
interventions, cells with a shorter doubling time
and non-diabetic patients (Table 5). The model
explained approximately 90% of the variation in
outcome (Nagelkerke’s R2¼0.90).
Adverse Events
One patient developed sepsis following implanta-
tion of BMSC requiring intensive hospital care.
The patient recovered uneventfully without overt
residual infection. Two patients died before final
follow-up, but apparently due to causes unrelated
to the nonunion treatment. One died within
3 months of the intervention due to an aorto-
enteric fistula, and the other died 3 years after the
intervention due to heart failure on a background
of tricuspid regurgitation. Another patient was
reported to have a benign gastric tumor 6 years
after the BMSC insertion. The tumor was excised,
and the patient was doing well during the latest
follow-up at 9 years.
Table 2. Overview of Carriers Used in the Study
Carrier type
Number of cases
(%)
b tri calcium phosphate with calcium
sulphate
16 (46%)
b tri calcium phosphate 6 (17%)
Calcium sulphate 4 (11%)
Hydroxyapatite 1 (3%)
Serum 8 (23%)
Table 1. Baseline Demographics and Clinical Characteristics
Parameter Value
Demographics
Sex Male 21 (60%), female 14 (40%)
Age at accident (years) Mean 45.2 (SD 12.4; range 16–71)
Age at cell implantation (years) Mean 50.6 (SD 12.5; range 17–75)
Time from accident to cell implantation (months) Mean 56.4, median 35 (range 12–396)
Fracture and nonunion characteristics
Site Femur 19 (54%), tibia 16 (46%)
Velocity High 20 (57%), low 15 (43%)
Open or closed Open 18 (52%), closed 13 (37%), Unknown 4 (11%)
Atrophic or hypertrophic Atrophic 29 (83%), hypertrophic 6 (17%)
Number of operations before cell implantation Mean 2.8, median 2 (range 1–14)
Number of cases with previous autologous bone graft or BMP Graft 10 (29%), BMP 0, Both 2 (6%)
Comorbidities
Smoking Yes 8 (23%), No 27 (77%)
Alcohol Yes 16 (46%), No 13 (37%), Unknown 6 (17%)
Diabetes mellitus Yes 5 (14%), No 30 (86%)
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Health-Related Quality of Life
The mean preoperative EQ-5D utility index was very
low (0.09; Table 6). The score increased significantly
by 0.34 at 1 year (p¼ 0.01), with no evidence of a
difference in benefit between patients who had and
who had not achieved union (p¼0.14 for interaction
between union and slope). An analysis of the five
dimensions of the EQ-5D showed noticeable improve-
ment in scores pertaining to anxiety/depression, pain/
discomfort, and usual activity, but minimal differ-
ences in mobility and no changes in self-care at
12 months.
DISCUSSION
In our study, 60% of patients with a recalcitrant
nonunion of fracture and very varied often complex
histories, achieved radiological union. Faster cell dou-
bling time, the absence of diabetes, fewer previous
surgeries, and lower age at cell implantation were
significant predictors for bony healing in these
patients. The overall union rate of 60% may seem low
compared to union rates in other studies of biological
enhancement treatments for lower limb fracture non-
unions, which typically range from 88% to 94%
(Table 7).
However, our case series represents a group of
patients defined to have severe “recalcitrant” nonun-
ions, for many of whom the next considered treat-
ment would be amputation. On average, the patients
in our study were around 10 year older, had one
extra previous surgery and 32 months more had
passed since their original fracture than typically in
other series (Table 7). Based on our analysis (Ta-
ble 5), the higher age and extra surgery would
reduce the odds of healing five-fold. Moreover, our
study included a three to five times larger proportion
of patients with diabetes than other studies (Table 7).
Diabetes was associated with a very poor prospect of
healing in our study, and accumulated evidence from
animal studies suggests that bone regeneration is
strongly reduced in animals with diabetes.14 Taken
together, these differences probably explain why the
overall healing rate in our study was lower than
others’. It also indicates that culture-expanded
BMSCs are no “magic bullet” for certain patients
Table 3. Univariable Analysis of Categorical Predictors of Union
Factor OR (95% CI) p-value
Gender (Male) 1.4 (0.27–7.0) 0.73
Fracture site (tibia) 1.7 (0.35–9.2) 0.50
Type of fracture (open) 0.82 (0.15–4.4) 1.0
Type of nonunion (hypertrophic) 3.6 (0.34–192) 0.37
Infection at insertion 7.46 (0.43 to 129) 0.48
Alcohol 1.1 (0.16–7.1) 1.0
Diabetes 0.12 (0.0022–1.4) 0.06
Smoking 0.39 (0.046–2.8) 0.39
Previous bone graft treatment 0.40 (0.06 to 2.3) 0.27
Previous BMP treatment 0.60 (0.06 to 2.3) 1.0
Carrier type - 0.61
OR is Odds Ratio, CI is Confidence Interval. p-values determined using Fisher’s exact test.
Figure 1. Example of a patient whose fracture healed. The patient was a 42 year old male who fractured his tibia in a road traffic
accident 8 years before cell implantation. In those 8 years, the fracture had four previous interventions. A: Pre-cell implantation. B:
Four months after implanting 5 106 BMSCs in a CaS carrier. C: 12 months after cell implantation the fracture has united.
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with recalcitrant non-unions, and better solutions are
still needed for those more elderly patients with
diabetes, for example.
The study also shows that longer in vitro cell
doubling time during culture expansion of BMSC
was related to reduced likelihood of achieving frac-
ture union, whereas the number of cells implanted
had no effect. Doubling time was reported critical in
a study comparing osteogenic potentials of culture
expanded human BMSCs.15 The study found consid-
erable donor variations of in vivo osteogenic poten-
tial and identified a longer cell doubling time during
in vitro expansion as the best predictor of poor
osteogenicity.16 Hence, our data might also help
define future quality criteria for BMSCs in bone
regeneration, with the cell doubling time of patients’
BMSCs as a potential biomarker to predict their
odds of achieving union before treatment. The lack
of relevance of cell numbers seems to be in contrast
to the study of percutaneous bone marrow grafting
in which larger numbers of injected cells increased
the odds of fracture union.9 However, the smallest
number of implanted cells in our study is two
million (range 2–10 million) which significantly
exceeds even the largest number of cells used in
that study (70,000). There remains no clear optimal
number of cells to implant for other cell therapies,
for example, in cartilage repair procedures used in
the clinic.16
Our study also found that three clinical or
demographic factors (no diabetes, lower age, and
fewer previous operations) predicted the chance of
union. As mentioned above, diabetes mellitus and
also age are well-known risk factors contributing to
nonunions17 and perhaps their persistence. The
number of previous treatments characterizes the
persistence of a nonunion, and therefore, its emer-
gence as a risk factor for failure to heal is expected.
The injury mechanism or type of fracture (“open” vs.
“closed”) were not significant predictors of nonunion,
in agreement with the findings of the SPRINT trial
for tibial fractures.18
The unrelated deaths and tumor in the present
study is in line with others; for example, a report
on the safety of stem cells for orthopaedic regener-
ation reported a tumor (of the liver) in their series,
which was likewise considered unrelated.19 The
lack of related serious adverse events in our study
highlights the safety of using autologous in vitro
expanded BMSCs to treat nonunions. BMSCs in
this study were grown for a maximum of three
passages to minimize the risk of genetic changes
associated with long-term culture and expansion.20
Cells were cultured in autologous serum, removing
risks of prion or virion transmission from bovine-
derived serum.20 In addition, the cells were
implanted locally rather than administered intra-
venously, reducing risks of aberrant remote prolif-
eration.21
Twelve months after cell implantation in our study,
the EQ-5D index had improved significantly by 0.34
points, suggesting substantial overall improvement for
this patient group. Despite this improvement, the EQ-
5D index remained relatively low, in line with a
Table 5. Results of the Multiple Logistic Regression Analysis
Factors Coeff. (95%CI) OR (95%CI) p-value
Age at cell implantation   0.15 (  0.36 to   0.02) 0.86 (0.69 to 0.98) 0.02
Number previous interventions   0.48 (  2.3 to   0.11) 0.62 (0.097 to 0.90) 0.008
Doubling time   0.19 (  0.63 to 0.01 0.82 (0.53 to 1.01) 0.07
Diabetes   4.9 (  11 to   1.5) 0.008 (3  10  5 to 0.24) 0.003
CI is Confidence Interval, OR is Odds Ratio. Coefficients, ORs and p-values determined using penalized logistic regression. For this
model, Nagelkerke’s R2 was 0.90.
Table 4. Univariable Analysis of Continuous Predictors of Healing
Factor
Union (median,
IQR)
Non-union (median,
IQR) OR (95%CI)
Nagelkerke’s
R2
p-
value
Age at accident 42.4 [37.7, 50.6] 53.9 [39.8, 57.3] 0.97 (0.91 to 1.02) 0.06 0.25
Years since accident to cell
implantation
2.3 [1.5, 3.9] 3.3 [2.8, 5.1] 0.92 (0.63 to 1.03) 0.08 0.17
Number of previous operations 2.0 [2.0, 3.0] 3.0 [2.0, 5.0] 0.58 (0.29 to 0.95) 0.22 0.02
Age at cell implantation 47.8 (14.1) 55.0 (8.8) 0.96 (0.89 to 1.01) 0.11 0.12
Cell number (106) 5.5 [5.0, 6.5] 5.0 [4.0, 6.0] 1.1 (0.78 to 1.6) 0.01 0.56
Cell doubling time (days) 5.1 [3.9, 6.0] 7.0 [3.7, 12.7] 0.87 (0.68 to 0.99) 0.20 0.04
IQR is Interquartile Range, OR is Odds Ratio, CI is Confidence Interval. OR and their 95%CI, Nagelkerke’s R2 and p-values
determined using penalized logistic regression
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previous study of patients with fracture nonunions.22
This finding highlights the substantial influence of
quality of life from a nonunion fracture.
The study is limited by being a report of a case
series and lacks the robustness of randomization
and evaluation of the outcome in a control group;
in addition there was great variability in the
patient group in terms of previous procedures, time
since fracture etc. Were a trial to be conducted
among a more homogenous group of patients pre-
senting with fewer previous procedures, the effect
of cells may be even greater. The use of four
different types of osteoconductive carriers can also
potentially influence the outcome of fracture union
and such a variety of carriers may be considered a
limitation. However, a subgroup analysis with the
five groups of patients (according to carrier types,
including one receiving no carrier) showed this
factor contributed no significant difference to the
clinical outcome.
The fact that there remained 40% of patients
who did not achieve union of their fracture follow-
ing cell therapy may indicate that this group of
patients had conditions that were particularly
unsuitable for this approach of treating with autol-
ogous cells. This could in part relate to the
environment that the cells were being implanted
into. Bajada et al.3 demonstrated that cells in the
vicinity of the nonunion site secreted increased
levels of the Wnt signaling inhibitor, DKK1. Since
Wnt proteins promote BMP-mediated osteoblastic
differentiation, production of DKK1 in vivo could
explain a decreased propensity for mineralization
and bone formation at a fracture site. An alterna-
tive approach for promoting osteogenesis may be to
select a sub-group of mononuclear cells from the
bone marrow; certainly, a Phase I/IIA trial, which
used granulocyte colony stimulating factor (G-
CSF)-mobilized peripheral blood CD34þ cells, has
shown encouraging results in nonunion patients
with healing in 71% of patients.23 A suggestion for
their success is that these cells have the ability to
differentiate into cells of not only osteogenic but
also vasculogenic and haematopoietic lineages. In
addition, if a particular patient has one of many
genotypes which may lead to a lesser likelihood of
osteogenesis, then perhaps any autologous therapy
for nonunion is doomed to fail and the use of an
allogeneic therapy would be beneficial in such
individuals.
In conclusion, one cell characteristic (faster cell
doubling during in vitro culture) and three patient
characteristics (lower age, not having diabetes, and
fewer previous operations) were strongly correlated
with bone healing in patients with recalcitrant
nonunion. Implantation of culture expanded-BMSC
to treat such nonunions was correlated with an
improvement in the patients’ general quality of life
and wellbeing. Further improvement in patient
selection or perhaps the use of an alternative cell
population, may aid outcomes in patients who
remain difficult to achieve unions in, such as the
more elderly patient and, or those with diabetes
mellitus.
Table 7. Comparison of Baseline Patient Characteristics and Union Rates Between Four Reports of Biological
Nonunion Treatments
Study Treatment
Age (Mean,
range)
Previous
surgeries (mean,
range)
Months since
injury (mean,
range)
Diabetes
(number/total,
%)
Clinical
union rate
(%)
Current Culture-expanded
BMSCs
50.6 (17–75) 2.8 (1–14) 56 (12–396 5/35 (14%) 21/35 (60%)
Pneumaticos
et al.22
Autologous bone
graft and/or
BMP-7
38.8 (17–78) 2.0 (0–11) 24.0 (6–317) Nd 94.3%
Kanakaris
et al.17
BMP-7 42.6 (19–78) 2.5 (0–11) 23 (9–317) 1/60 (2%) 61/68 (89.7%)
Hernigou
et al.12
Percutaneous bone
marrow injection
40.0 (18–78) 1.1 (0–2) 8.7 (6–12) 3/60 (5%) 53/60 (88%)
The mean values cited for Pneumaticos et al., a meta-analysis, are the pooled means of all 13 studies in that review reporting the
characteristic; nd is not documented
Table 6. Change in EQ-5D at 1 Year From Cell Implantation
Outcome Mean pre-op (SD) Mean post-op (SD) Difference (95%CI) p-value
EQ-5D index 0.09 (0.45) 0.32 (0.41) 0.34 (0.11 to 0.58) 0.01
Difference calculated using random intercept multilevel model. This difference does not equal the difference between the pre-op and
post-op columns but does provide a better estimate by properly accounting for repeated measures.
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